Introduction
============

Dementia represents a general term used to describe a chronic and substantial decline in two or more areas of cognitive function related to cellular and subcellular changes in the brain ([@b56]) underlining the multifactor origin of dementia syndrome ([@b188]). Imaging techniques (IT) supporting the diagnosis of different dementia subgroups of are moving from a negative, exclusionary role ([@b4]) to one that reveals positive diagnostic, therapeutic, and/or prognostic value. FIT can offer an important impact in the treatment of dementia ([@b219]).

Cerebrovascular changes (CVC) represent a common symptom of the physiological aging process ([@b217], [@b218], [@b212]; [@b215], [@b216]), and cerebrovascular risk factors are strongly associated with dementia including Alzheimer's disease (AD) ([@b43]; [@b49]; [@b227]). About 40% of the population who met the diagnostic criteria for probable AD also show markers for cerebrovascular disease (CVD) ([@b49]; [@b93]; [@b105]; [@b118], [@b119]). In addition, different well recognized risk factors for CVD are strongly associated with AD and have elucidated the impact of cerebrovascular lesions on the development and progression of dementia in AD ([@b104], [@b105]) suggesting that there exists a relationship between elevated midlife blood pressure and late-life AD ([@b58]). With the recent availability of several effective pharmaceutical agents for treatment of dementia undergoing clinical trials ([@b239]), a new area will be entered emphasizing the increasing need to diagnose dementia in its more earlier stages ([@b262]), so that new IT gain increased importance in last years ([@b79]; [@b182]). FIT represent the potential to enable identification of more subtle pathological (sub) cellular changes earlier during the disease course ([@b26]; [@b23]). To better use these new diagnostic modalities, a thorough understanding of the physiological changes in the aging process and of the pathophysiological steps in dementia is needed.

Physiological background as related to dementia
===============================================

The coupling between neuronal activity and cerebral metabolism
--------------------------------------------------------------

Current physiological-based hypotheses regarding the activity-/metabolism-coupling in different activated states of the brain ([Figure 1](#fig1){ref-type="fig"}), whether activated neurons in the brain significantly increase their consumption of oxygen (cerebral metabolic rate, CMR~O2~) or whether they exploit anaerobic metabolism for energy production, have been disputed ([@b219]). In particular, glutamate, released by activated neurons, would be the pivotal element coupling glucose consumption (CMR~glc~) to excitatory neuronal activity (NA) ([@b185]) involving glutamate uptake into astrocytes, resulting in an increased intracellular Na^+^ concentration $(\lbrack{Na}_{i}^{+}\rbrack)$ and activation of the Na^+^/K^+^-ATPase ([@b32]; [@b20]). Such increased metabolic demand linked to disruption of Na^+^ homeostasis may activate glucose uptake and glycolysis in astrocytes ([@b32]). Therefore, astrocytes appear to function as a network for concentrated neurometabolic coupling through Na^+^~i~ gerneration and increased metabolic turnover ([@b20]). Indeed, a stoichiometric relation has been reported between glutamate- and glucose-uptake by cultured astrocytes and likewise between glutamate cycling and CMR~glc~ in mice cortex ([@b185]). This proposed model is consistent with the view that during NA, glutamate uptake into astrocytes leads to increased CMR~glc~ and lactate production, which can be subsequently used by neurons to meet their energy needs ([@b140]).

![Neurobarrier coupling in the brain: The potential neurovascular and neurometabolic coupling ([@b131])\
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NA applies to a spectrum of energy requiring processes including action potential propagation, neurotransmitter release and up-take, vesicular recycling, and maintenance of membrane potential, providing a conceptual framework for the interpretation of new experimental data on the molecular aspects of cerebral energy metabolism ([@b243]). All these processes are involved in short-term neuronal information encoding, but the relative distribution of energy among them and how the different subclasses of neurons in a specific cortical region contribute to the overall energy consumption process remains an open question. At present, FIT identifies the location of changes in NA, but provides still no insight into the total NA involved in a process ([@b140]; [@b141]). In addition, the stoichiometric relationship between glutamate cycling and oxidative glucose metabolism argues for a quantitative coupling between NA and cerebral metabolism and would be in favor of metabolism as an index of NA ([@b141]).

γ-Aminobutric acid (GABA) is the major inhibitory neurotransmitter in the central nervous system (CNS). GABA does not couple inhibitory NA with CMR~glc~, as does glutamate for excitatory neurotransmission, and suggest that GABA-mediated synaptic transmission does not contribute directly to signals in IT based on deoxyglucose ([@b32]). In addition, anatomical and physiological arguments have been put forward to support the physiological concept that inhibition might involve lower metabolic demands ([@b140]; [@b32]). Based on their reduced number, strategic position, and increased efficiency, inhibition provided by synapses from GABAergic interneurons in the cortex might simply involve less energy expenditure upon activation than the excitatory drive (Koistinaho 2003). Thus glutamate, by activating GABA neurons, could lead to an overall inhibitory NA in a specific cortical area; yet glutamate release and uptake by astrocytes would stimulate glycolysis in astrocytes and constitute a sufficient signal coding for increased activity of GABAergic neurons as well ([@b32]). It would therefore appear that the most relevant, and possibly sufficient imaging signal, linking NA (both excitatory and inhibitory) with metabolism is glutamate, which would mediate the appropriate metabolic coupling both for excitatory and inhibitory neurons ([@b140]).

The neurovascular coupling
--------------------------

Experimental studies provide evidence for a cascade of physiological events for NVC whereby glutamate, leaking from active synapses, activates glutamate receptors on astrocyte membranes, leading to an elevation of intracellular Ca^2+^ $\lbrack{Ca}_{i}^{\text{2+}}\rbrack$, which in turn leads to the biochemical production and release of eicosanioids, which represent potent vasodilators (Bonvento et al 2002). Interruption of any stage of this cascade reduces the cerebral blood flow (CBF) response severely, without affecting the neural response ([@b140]; Bonvento et al 2002).

Advances in this research field have demonstrated that release of the major excitatory neurotransmitter glutamate initiates physiologically diverse signaling processes between neurons and astrocytes, and that this signaling could be crucial for the occurrence of molecular imaging signals, although the neurovascular importance of these mechanisms is not clear (Bonvento et al 2002). Re-uptake of glutamate from the synaptic cleft into astrocytes is mediated by the specific high-affinity glial transporters GLAST (glial glutamate aspartate transporter) and GLT-1 (glutamate transporter 1), which are particularly enriched in brain areas with high glutamatergic activity and are essential to maintain glutamate levels below neurotoxicity limits (Schmidt et al 2004).

A positive linear correlation has been reported between the integrated electrophysiological activities, ie, summed evoked potentials (EP), at different frequencies of NA stimulation and CBF response ([@b7]), demonstrating that CBF response did not depend on NA intensity when duration was held constant (time-intensity separability) ([@b7]). However, mathematical modeling of the relationship between CBF and electrophysiological response to somatosensory stimulation revealed not only a linear but also a nonlinear component in this NVC ([@b7]). Indeed, changing the stimulus duration, but not the intensity, results in a different pattern of responses for CBF and somatosensory EP, each one exhibiting maximal amplitude for different stimulus durations ([@b7]). Moreover, activation-flow coupling seems to be dependent on the interstimulus interval ([@b6]): CBF response is less important when interstimulus time is short, while somatosensory EP's response is not altered, suggesting that hemodynamic response but not neuronal response is refractory ([Figure 2](#fig2){ref-type="fig"}). The spatial extent of activation in functional magnetic resonance imaging (fMRI) experiments has been found to correlate to a reasonable extent with NA measured neurophysiologically, considering the differences between these IT ([@b47]).

Glutamate might not be the only neurotransmitter that is involved in NVC via glutamate transporters, an increased Na^+^~i~ followed by activation of a specific glial Na^+^/K^+^-ATPase isozyme ([@b35]). Acetylcholine (ACh) that is produced by the basal forebrain neurons increases CBF in specific cortical (mainly frontoparietal) and subcortical areas ([@b9]). This subcellular effect might be due to the direct contact of basal forebrain neurons or due to the presence of cholinergic receptors on nitric oxide synthetase (NOS)-containing neurons ([@b9]) and underlies a physiological age-related impairment of NVC ([@b81]). The neuronal system also plays an important role in the coupling mechanism between NA and functional CBF response ([@b244]) being attributable to the alterations of mechanisms of coupling via the cholinergic system not only in AD, but also in physiological aging ([@b153]). Although the exact (sub) cellular mechanisms are unclear, pathological depletion of Ach is therefore also encountered in vascular dementia. It seems that vascular lesions damage cholinergic neurons ([@b153]).
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The coupling between cerebral blood flow and cerebral metabolism
----------------------------------------------------------------

The hypothesis of NVC is proposed initially by Roy and Sherrington in 1890 (cited in [@b256]) that activity-induced increase in glycolysis mediates the increase in CBF by mechanisms linked through the near-equilibrium relationsship between cytosolic NADH/NAD+ and the lactate/pyravat ratios ([@b257]). There is evidence that the intracellular NAD+/NADH and the related extracellular ratio of lactate to pyruvate play an importance as products of cerebral metabolism as well as chemical stimuli are key factors that determine CBF rate ([@b257]; [@b5]). CBF in the activated brain is regulated by the need to support very specific and vital reactions such as glutamte uptake and cycling by astrocytes ([@b257]). CBF, however, may increase without significant change in local metabolism, and may increase much faster than the accumulation of the metabolic end-products ([@b141]). The regulation of coupling should thus involve physiological mechanisms that are independent of energetic substrates ([@b140]). CBF changes in the physiologically stimulated brain is thus related to changes in glyclolysis predominantly in astrocytes and is aimed to balance the cytosolic NADH/NAD+ ratio ([@b257]). Neurogenic stimulation via perivascular nerve endings may act as a rapid initiator, to induce a moment-to-moment dynamic CBF adjustment to the metabolic demands, and further maintenance of these adjusted parameters is ensured by metabolic and chemical factors ([@b207]; [@b265]). Constrictions appears spatially restricted, maximal at the level of neurite apposition, and is associated with contraction of surronding smooth muscle cells, providing the first evidence for neuronal regulation of vascular sphincters ([@b196]; [@b29]). Vascular cells are functionally linked to the neural tissue ([@b263]), making them essential members of the diverse family of brain cells that together constitute the neurovascular unit: Perivascular nerve endings were identified in the outer smooth muscle layer of the cerebral arteries, arterioles and veins ([@b207]). Their axon terminals contain a large variety of neurotransmitters, often co-localized in synaptic vesicles ([@b207]). Stimulation of these nerves results in a release of transmitters into narrow neuromuscular synaptic clefts of the cerebrovascular smooth muscles, close to specific receptor sites in the vessel wall ([@b207]). Several vasoactive molecules have been implicated in two types of regulation: (i) a local metabolic regulation exerted by NO, arachidonic acid derivates and adenosine or (ii) a loco-regional neurogenic regulation exerted by classical neurotransmitters and peptidergic neuromodulators ([@b199]). Based on the fact that vascular responses to NA are extremely fast, neurogenic regulation and NO appears to represent major candidates for a role in the dynamic adaptation of CBF ([@b176]). This context is elegantly illustrated in that NA causes vasodilatation through the ability of specific subsets of NO-producing GABA interneurons to transmute neuronal signals into vascular responses and further suggest that they could act as local integrators of NVC (Ranicillac et al 1996; [@b29]; [@b264]).

Highly regulated metabolic interactions occur between neurons and astrocytes, providing a conceptual framework for the interpretation of new experimental data on the molecular aspects of brain energy metabolism ([@b140]). Through the use of autoradiographic techniques in animal-model's brain activity at rest, a linear relationship between CBF and CMR~glc~ has been demonstrated (Zlokovic et al 2004). A quite similar correlation has been found between CBF and CMR~O2~ at the resting state ([@b199]). Such a relationship between CBF and neuronal metabolism, so-called "flow-/metabolism-coupling," is observed whatever technique or species is used ([@b71]; [@b233]). Although the existence of a flow-/metabolism-coupling at rest is well accepted, the parallelism between CBF and cerebral metabolism appears to be far from clear during NA paradigms. There is considerable heterogeneity, for example, in the density of brain capillaries and in the distribution of mitochondria responsible for aerobic metabolism ([@b168]). Coupling between CBF and CMR~glc~ is quite well preserved in a vast majority of cerebral regions that are activated following either mechanical or electrical stimulation under experimental conditions, but several uncoupled situations have been observed in subcortical regions such as the thalamus, a brain region in which the CBF response is found to largely exceed that one of CMR~glc~ under physiological conditions ([@b245]; Buxton et al 2000; [@b70]). Hemodynamic responses correlate better with local mean field EP, rather then local spiking rates, suggesting that CVC is dominantly driven by input synaptic activity rather than output spiking activity ([@b128]). The primary expenditure of energy is required to restore the ion gradients degraded during NA ([@b141]; [@b27]). The intracellular -- extracellular Na^+^-gradient is far from equilibrium, so pumping Na^+^ against this gradient represents a strongly uphill reaction in a thermodynamic sense ([@b27]). For this reason, the most costly aspect of NA is likely to be excitatory synaptic activity in which glutamate opens Na^+^ channels ([@b140]; [@b27]). Indeed, the action of the Na^+^/K^+^ pump is thought to consume a large fraction of the ATP energy budget in the brain ([@b141]; [@b5]). The maintenance of such an energy state despite constant metabolic rate in the somatosensory cortex suggests that the generation of EP does not require measurable amounts of energy under pathological conditions, like in postischemia or poststroke conditions ([@b245]). Several technical points have been proposed to explain such pathological situations of uncoupling between CBF and CMR~glc~ under experimental conditions and to exclude nonpathological conditions: (i) a difference of the temporal resolution between imaging techniques for CBF versus CMR~glc~; (ii) a low spatial resolution not allowing the detection of very small regions of interest; and (iii) a different size of the activation foci for CBF and cerebral metabolism. For this latter point, a larger activation is needed in comparison to a region delineated by the CMR~glc~ changes; this can also result in misleading interpretations ([@b87]). Therefore, the hypothesis of a nonlinear coupling between CBF and CMR~02~ has been proposed ([@b141]): With increased NA, CBF increases substantially, while CMR~02~ increases only moderately, so the oxygen extraction fraction (OEF) is reduced ([@b58]). In addition, a nonunit gain relationship is actually expected due to the diffusion limitation of oxygen supply. However, astrocytic lactate can replace glucose as an energetic supply for neurons during activation has suggested that, at least, part of the glucidic metabolism could be anaerobic recycling NAD+ via the reduction of pyruvate to lactate despite the presence of sufficient oxygen and export the lactate ([@b181]). It seems that not all carbohydrate taken up by the brain is oxidized during activation, as brain lactate metabolism appears to lower the balance of O~2~-to-carbohydrate uptake ([@b94]). Lactate seems then to be imported into the neuron and to feed oxidative metabolism in neurons ([@b94]). Under these conditions one can hypothesize nonparallel variations of CMR~02~ and CMR~glc~. If CBF is a robust index of NA, it might be tightly coupled to both, metabolism and NA, and might thus not vary alone while the two other parameters are stable ([@b140]; [@b218]). However, experimental data suggest a situation of uncoupling between CBF and, at least, metabolism under pharmacologically induced conditions indicating that the involvement of neuron-derived nitric oxide (NO) in coupling flow to somatosensory activation is region-dependent, and that under nNOS inhibition, CBF and CMR~glc~ may vary independently during NA ([@b45]); therefore lactate, rather than glucose, may be the preferred fuel for neuronal metabolism ([@b228]). However, the large carbohydrate uptake by the brain during recovery from maximal activation suggests that brain glycogen metabolism is important in the transition form rest to exercise, since this would explain the significant post-activity decrease in the O~2~/carbohydrate uptake ratio ([@b95]). Therefore, circulating lactate is used by the brain at euglycemia, with sparing glucose ([@b228]).

The neurogenic regulation of coupling by acetylcholine
------------------------------------------------------

Ach is a potent vasodilator innervating local cortical nitroxidergic interneurons, cerebral capillaries and microarterioles ([@b77]). Cholinergic innervation mostly originates from the nucleus basalis of Meynert ([@b152]). The existence of such innervations, associated with the presence of cerebrovascular muscarinic receptors, has allowed to propose the implication of an ascending cholinergic system in the regulation of cortical CBF ([@b45]). If cholinergic innervation is necessary to maintain CBF control in specific brain regions, degeneration of basal forebrain cholinergic neurons, as in AD, could therefore uncouple NA from CBF (or alter the nature of the coupling) locally as well as in specific remote regions ([@b83]; [@b22]). Altered CBF response in such specific brain regions could not directly be interpreted as altered NA ([@b77]; [@b202]). One may hypothesize for these reasons that up-regulation of eNOS directly augments the neuron to vascular communication or that the increased levels of vasorelaxing NO only improve the endothelial site of the coupling resulting in a better responsiveness ([@b202]). The clinical finding of pharmacological effect of acetylcholine esterase (AchE) inhibition in patients suffering from a vascular related dementia may support the latter notion ([@b187]). Moreover, the nonuniform cholinergic cortical innervation could explain the regional variability in NVC in certain circumstances ([@b77]).

AchE inhibitor physiostigmine has been found to increase basal CBF and to decrease CMR~glc~, leaving CMR~O2~ unchanged ([@b212]). Conversely, decreased CBF and increased CMR~glc~, a phenomenon that also illustrates a situation of uncoupling, follows systemic injection of the muscarinic antagonist scopolamine to humans or animals ([@b82]). [@b222] suggest that the response to cholinergic activation may therefore result from the balance between the direct hyperpolarizing action of ACh and the depolarizing modulation of glutamate from the neighboring neurons, in addition to the modulation of the interglial communication pathway and/or the ionic traffic across blood vessels. In addition, during somatosensory activation, increased CBF has been found to be abolished by pharmacological intervention (eg, by scopolamine or by bromopyruvate) such as inhibitors of ACh synthesis, and to be restored by physiostigmine ([@b244]). Again, the neuronal response under pharmacological manipulation in these experimental studies is not measured through electrophysiological recordings but assumed by the preservation of the metabolic response ([@b244]). Therefore, one cannot conclude on an uncoupling between CBF and NA but only between CBF and cerebral metabolism under these conditions until all three parameters have been measured.

AchE activity in cerebral cortex is mainly due to the expression of this enzyme in cholinergic neurons and their axons ([@b76]). Intrinsic cholinergic neurons of the basal cortical pathway participate physiologically in the regulation of CBF responses ([@b244]). Indeed, the direct stimulation of the substantia innominata or the nucleus basalis of Meynert elicits an increased cortical CBF that is not associated to a parallel change in CMR~glc~ ([@b249]) being hypothesized to be implicated in the brain parenchyma during NA, suggesting that AchE modulates glial activation and CBF. In addition, nucleus basalis of Meynert lesion studies in animal-models demonstrated to decrease cortical CBF ([@b186]). In contrast, it has been shown that lesions of the nucleus basalis of Meynert do result in an unexpected preservation of CMR~glc~ associated to an increase in the density of GLUT3 (glucose transporter 3) glucose transporters in the cortex ([@b225]). This could be of great importance in pathological situations, where the cholinergic system is supposed to be degenerated as, for example, in degenerative dementia with consecutive loss of cholinergic neurons located in basal ganglia, particularly in the nucleus basalis of Meynert ([@b76]). As the ascending cholinergic system appears to be involved in the neurogenic regulation of CBF and/or CMR~glc~, interestingly, ACh has been demonstrated to interact also with a local, nitroxidergic, and metabolic regulation ([@b76]).

The local regulation of coupling by nitric oxide
------------------------------------------------

NO, first discovered as the "endothelial-derived-relaxing-factor", is supposed to be implicated both in the regulation of neuronal activity, CBF, and metabolic adjustments ([@b62]). NO is synthesized by three isoforms of NOS and has been localized next to the cerebral vessels, within nervous fibers suggesting a direct effect of NO on the CVsystem ([@b19]) and nNOS inhibitors allow demonstrating reductions in resting CBF as well as in CBF responses to somatosensory activation ([@b133]). Moreover, nNOS inhibitors failed to modify either the CMR~glc~ response or NA as assessed by somatosensory EP ([@b42]) supporting the existence of independent mechanism for the regulation of CBF and cerebral metabolism ([@b133]). Although NO participation in NVC is widely accepted, its exact mechanism of action remains yet unclear ([@b230]). Since NO serves as a retrograde messenger in synapses, one source of NO could be a leakage from synaptic clefts and rapid diffusion from active synapses to arterioles ([@b137]). As capillaries are much closer to pyramidal neurons than arterioles, diffusion might be adequate to provide the pyramidal neurons with nutrients from capillaries, but ineffective in delivering metabolic messages to the CBF gate at the terminal arteriole ([@b216]) ([Figure 3](#fig3){ref-type="fig"}). Alternatively, NO could be produced by specialized periarteriolar neurons that are activated by direct stimulation from collateral axons, or by leaked neurotransmitters form active synapses ([@b253]). In support of this notion, NOS containing neurons are located close to pyramidal cells and vary in density consistent with the variation of microvasculature density ([@b242]). In addition, a network of fine fibers and staining for NOS is found around arterioles, suggesting that NOS-containing terminals provide a link between active pyramidal cells and relatively remote terminal arterioles ([@b242]). NO is continuously released by endothelial cells into the vascular system; but advanced age followed by the presence of vascular risk factor causes a decreased CBF, involving microvasculopathy with impaired NO release, which in turn results in regional metabolic dysfunction ([@b242]). Whether the control of CBF by NO is implemented through simple diffusion or through specialized networks (neuronal or glial) should determine the degree to which the activity of clusters of neurons will produce similar amplitudes and temporal profiles of CBF changes ([@b9]) that can be visualized in FIT ([@b102]). Another factor in this complex equation is the nonuniform distribution of NO-producing neurons in different cortical areas (see for example [@b217]). However, these findings suggest that vascular pathology plays a crucial role in the pathogenesis of so-called neurodegenerative dementias ([@b264]). Inflammatory responses are commonly found in the brain under a variety of neurodegenerative dementias, including AD and DLB, in which up-regulation of NOS expression, suggesting overproduction of NO, is found in neurons and glia ([@b242]). NO is thought to be involved in such neuroinflammation due to its free radical qualities, which compromise cellular integrity and viability via mitochondrial damage ([@b242]; [@b209]; [@b209]).

![Neurovascular coupling mechanisms during cerebral somatosensory activity.](ndt0403-585-03){#fig3}

It is also not known whether NO is a direct mediator of enhanced CBF or has only a modulatory ("permissive") role. It remains unclear whether NO determines the vascular response quantitatively, or it is necessary for other mediators to exert their effect ([@b133]). In the rat cerebellum, decreased CBF response leads to inhibition of NO indiscriminately, indicating that NO acts as a direct mediator of local CBF control ([@b132]). In contrast, in the rat somatosensory cortex NO has a modulatory effect, since the application of NO restored the CBF response after inhibition of NOS ([@b36]) suggesting that NVC processes might vary across the brain.

Although no study has addressed the effect of nNOS inhibitors on the physiological parameters of interest in the same model, all these data taken together suggest dissociation between vascular and metabolic/electrophysiological responses under nNOS inhibition ([@b69]) as underlined by the use of knockout mice lacking the genes for either eNOS or nNOS ([@b10]; [@b25]). Pharmacological manipulation of NO through the blockade of its synthesis allows demonstrating region-specific-effects; indeed, while cortical CBF response to cerebral nNOS inhibitors decreases activation, the vascular response is not altered in the thalamus ([@b36]) suggesting the existence of a complex mechanism in which the involvement of NO in coupling differs form one region to another.

Altered cerebrovascular dynamics in physiological aging
=======================================================

The vascular pathology seen in physiological aging process can be clinically silent or can lead to vascular compromise resulting in cerebral ischemia or even stroke representing probably the basis for alterations in NVC ([@b81]; [@b240]). However, cerebrovascular risk factors may cause asymptomatic brain injury, strengthen the genetic risk with AD and possibly accelerate neurodegeneration-related processes ([@b46]) suggesting that these two diseases may act cumulatively or synergistically to cause clinical dementia ([@b46]).

Ultrastructure of the cerebral vasculature
------------------------------------------

The compromise to the ultrastructural integrity of the cerebral vasculature in physiological aging process is mainly the result of arteriosclerotic changes, fibrohyaline thickening of the vessel wall, necrosis of smooth muscle cells and thickening of the basement membrane, that gradually increase with age ([@b143]; [@b81]). Although sclerotic changes correlate with the degree of hypertension, age seems to be an independent risk factor ([@b143]). These morphological changes decrease the elasticity and compliancy of affected vessels, which include capillaries, larger arterioles and cerebral arteries ([@b110]). Venous alterations that accompany aging, known as periventricular venous collagenosis, are also found in about 65% of the population over 60 years old, and can occlude veins completely in severe cases ([@b159]). There is also an increase in the tortuosity of some vessels with physiological aging, most notably in the arteriovenous-capillary bed, as well as changes in the density of capillaries and arterioles, but this effect have not yet been observed in venules ([@b81]).

Resting cerebral blood flow
---------------------------

Aging is associated with a rarefaction of the microvasculature followed by a significant decrease in resting CBF in the cortical and subcortical parenchyma reducing metabolic support for neuronal signaling particularly when levels of neuronal activity are high ([@b48]; [@b190]; [@b195]). Using positron emission tomography (PET), CMR~O2~ demonstrates a significant decline during physiological aging process predominantly at the left superior temporal cortex and more marked in the association cortices of the left hemisphere ([@b190]; [@b195]). Evidence that age-related declines in CBF are not specific for neuronal function is provided by the demonstration that aging decreases both basal CBF and the increase of CBF normally accompanying neuronal stimulation ([@b195]). However, considering the significance of age-related changes in CBF and/or metabolism, two caveats exist: (i) aging-related cerebral atrophy may confound the interpretation of imaging studies of CBF ([@b65]); and (ii) a decreased local CBF in the aged brain could be a secondary rather than a primary factor of a decline in neural function, especially in the grey matter ([@b96]). However, there has been discussion as to whether neuronal loss subtending gross structural changes in aged healthy volunteers fully explains the regional changes measured with functional imaging ([@b248]). Contrary to the widely belief, neuronal concentration remains essentially constant during normal aging process, but neuron size decreases -- presumably as a result of reduced dendritic arborization and dendritic spine concentration ([@b8]) -- and the number of glial cells decreases ([@b17]) occuring with substantial variability ([@b248]).

Vascular reactivity
-------------------

Specific, age-associated decrease in the vascular reactivity of cerebral vessels to various chemical modulators, including carbon dioxide (CO~2~) is seen ([@b14]). Generally accepted, increased blood CO~2~ results in dilatation of cerebral arterioles under physiological conditions ([@b250]). Decreased vascular reactivity to hypercapnia has been observed in aged animals or humans with and without risk factors for arteriosclerosis ([@b258]). In PET of rCBF, a significant decrease in a total vascular response from a hypocapnic to a hypercapnic state is observed in older individuals as compared to younger ones ([@b165]; [@b195]). In aged animals, there is a reduced degree of vasodilatation in response to cerebrospinal fluid perfusion of the vasodilators adenosine, ACh and bradykinin ([@b150]).

The exact mechanism of age-related changes in vascular reactivity have not been elucidated, although it has often been suggested that aging-related effects may be most significant for agents that act by modulating the release of endothelium-derived relaxing factor (NO) ([@b197]; [@b198]; [@b193]). But, the wall of the cerebral arterioles undergoes atrophy during aging and there is a decrease in the distensibility of the cerebral vessels, which is mainly based on alterations of their composition with a disproportionate reduction of the distensible elements ([@b72]). Therefore, cerebral vessels in older subjects may not react as effectively in response to dilator stimuli such as hypercapnia or those released during neuronal activation ([@b197]). In addition to such structural changes, mechanisms that might affect vascular reactivity independent from NA include the gliosis that accompanies tissue scarring from damaged brain tissue, and the disruption of long-range aminergic and cholinergic fibers that innervate the vasculature (Czosnyka et al 2004). Thus, altered NVC can occur close to a damaged brain region even in apparently normal tissue ([@b11]). Moreover, age-related changes in vascular reactivity might vary across brain regions ([@b90]). A study that compared the resting and stimulus-evoked increases in CBF ipsilateral in both the parietal and frontal cortex of young rats demonstrated altered effects in the frontal cortex of aged rats (Ranicillac et al 2003). This finding suggests that the structural and functional changes that occur in vessels during physiological aging cause disability of cerebral microvessels to deliver nutrients and oxygen to the brain optimally, thereby affecting the mitochondrial ability to respond to anoxia ([@b165]) mirroring the nonuniform distribution of arteriosclerosis in the brain (see for example [@b183]).

There is an age-related dissociation of calbindin and the glutamate receptor GluR2 within cholinergic basal forebrain neurons, implying that these molecules act synergistically to induce excitotoxic cell death during aging, and possibly during AD ([@b165]). Choline acetyltransferase (ChAT) activity and cholinergic basal forebrain neuron number are preserved in the cholinergic basocortical system and up-regulated in the septohippocampal system during early as compared with end-stage AD ([@b165]). In contrast, the number of cholinergic basal forebrain neurons containing nerve growth factor (NGF) receptors is reduced early in the disease suggesting a phenotypic silence and not a frank loss of neurons ([@b165]). In end-stage AD, there is a selective reduction in trkA mRNA but not p75(NTR) in single cholinergic basal forebrain cells suggesting a neurotrophic defect throughout the progression of AD ([@b165]; [@b264]) and indicating that multiple factors may play different roles in the consecutive dysfunction in aging and AD ([@b165]).

Additional significance of aging-related changes in vascular plasticity
-----------------------------------------------------------------------

Aging-related changes in the vasculature also influence other critical aspects of neural function and plasticity ([@b142]). The microvasculature is critically involved in regulating adult neurogenesis, as a source of local and blood-borne factors providing an appropriate environment for neurogenesis stimulating the proliferation and differentiation of progenitor cells ([@b217]). For this reason, the role in brain repair after ischemic events is under discussion: The production of new granule neurons in the subgranular zone of the adult dentate gyrus occurs within "neuroangiogenic foci" where neuronal, glial and endothelial precursors are divided into tight clusters ([@b215]; [@b242]). This association between endothelial and neuronal proliferation in the subgranular zone suggests that signals originating from somatic tissues or from the CNS act simultaneously to stimulate neurogenesis and angiogenesis, or that the initiating signal activates proliferation of only one cell type, which then stimulates proliferation of the other ([@b215]). In addition to trophic factors, endocrine growth factors like insulin-like growth factor (IGF-1) influence neuronal turnover in the adult brain, regulating neurogenesis, and the decline in neuronal turnover during advanced aging may be the result of decreased IGF-1 levels ([@b234]).

Pathological-induced alterations of cerebral blood flow and/or metabolism regulation
====================================================================================

Cerebral blood flow
-------------------

The collective findings discussed so far suggest that brain hypoperfusion precedes the hypometabolic and neurodegenerative changes ([@b205]), investigating early stages of dementia in which advanced neurodegeneration have not yet evolved. In the opposite sequence, neurons exposed to oxidative stress and impaired energy substrate delivery would further reduce CBF to accelerate neuronal death, a mechanism inconsistent with cellular survival ([@b264]). The use of cerebral metabolism as an index of NA may not always be valid, particularly when the biochemical steps related to cellular energy and cell-membrane turnover is altered like in AD ([@b224]). Therefore adequate measurement methods of NA would be needed to examine the preservation or alteration of NVC in these pathological states: in these selected situations, CBF variations appear to be non reliable indices of cerebral metabolism and, putatively, of neuronal activity ([@b71]). This may limit the use of activation IT in pathophysiological conditions ([@b141]). Another major problem is represented by the yet unknown coupling between oxidative metabolism and CBF: Techniques such as fMRI and near infrared spectroscopy (NIRS), that record a complex signal linked both to variations of CMR~02~ and CBF, might thus fail to distinguish between these two parameters ([@b71]).

Specific pattern of reduced CBF and metabolism have been demonstrated for several subtypes of dementia ([@b223]). For a number of authors, decrease of CBF and glycolytic metabolism are tightly correlated to the severity of the disease ([@b106]; [@b184]). Alterations of CBF and cerebral metabolism have been presented over the years as parallel events that should directly reflect the local loss of neurons and, in turn, the decrease in the local metabolic demand ([@b60]). However, uncoupled variations of resting CBF and metabolism exist in AD ([@b170]). In fact, a slight increase in CMR~O2~, suggesting a so called "misery perfusion", has been found in some brain regions of AD ([@b170]). Moreover, behavioral activation and CMR~glc~ measurements by PET suggest that the regional hypometabolism found in AD is not the result of neurodegeneration, but appears to precede it ([@b47]).

Though neuronal loss alone cannot explain the cerebrovascular and metabolic alterations observed in AD, the pathophysiological mechanisms, which alter CBF and/or local metabolism, are still unknown (Nixa et al 2002; [@b93]), but it seems that this phenomenon may be an early event in the pathogenesis of AD. Different working hypotheses have recently been suggested, stressing the importance of alterations of the ascending cholinergic pathway and of endothelial functions as well as of pathophysiological perturbations associated with β-amyloid protein (AP) over-expression ([@b189]). It is thus quite tempting to propose that two of the most common neuropathologic landmarks of AD, namely, cholinergic dysfunction and AP deposition, may in fact depend on the integrity of local lipid homeostatic processes, which in turn are strongly dependent upon proper lipid delivery by the apoE transport system ([@b189]).

The argument that hypometabolism in AD may elicit microvascular changes at some point is not supported by a considerable number of animal experiments. But chronic cerebral hypoperfusion can trigger oxidative stress, energy metabolic deficits, and memory loss before any neuronal structural pathology materializes ([@b33]; [@b238]), whereas there are no data that we are aware of that indicate the reverse process can or does occur. Moreover, the recent discovery of "neuroglobin" in rodent and human brain could partly explain why CA1 hippocampal neurons are exquisitely sensitive to hypoperfusion leading to hypometabolism ([@b33]; [@b238]). Neuroglobin in brain appears to act much like myoglobin in cardiac muscle cells; it aids oxygen diffusion to the mitochondria ([@b33]). Decreased tolerance of CA1 to ischemia may be due to lower oxygen supply resulting from less available neuroglobin, whose lowest expression is in the hippocampus ([@b33]). Consequently, brain hypoperfusion could reduce neuroglobin levels in CA1 and initiate mitochondrial oxidative stress ([@b33]).

Cholinergic pathways
--------------------

Cholinergic pathways projecting from basal forebrain regions to the hippocampus and neocortex are believed to play an important role in learning and memory processes ([@b18]). In patients with AD, the cholinergic system of the basal forebrain, including the areas of projection, is disrupted and/or altered ([@b39]). Moreover, as direct stimulation of the nucleus basalis of Meynert induces a major increase in CBF in the cortex without variation of the glucose metabolism, thus suggesting a preferential regulation of CBF by this region ([@b15]). Interestingly, a reduction in the density of the muscarinic receptors within cerebrovascular bed has been reported in AD, a situation that, associated to the parallel decrease in the density of contacts between cholinergic terminals and nitroxidergic cortical interneurons, could be responsible for an uncoupled state between CBF and cerebral metabolism ([@b63]). Such a situation might be exacerbated by the alterations of the modulation of the cholinergic system of the nucleus basalis of Meynert, for example by galanin or GABA, known to modify the functional input of the cholingeric system onto CBF regulation ([@b15]). These data indicate that the cortical neurodegenerative changes occur before the deposition of AP ([@b63]).

Glucose pathways
----------------

Glycolytic enzymes and glucose transporters present at the level of the blood--brain barrier (BBB) and neurons also appear to exhibit an abnormal function during AD ([@b112]; [@b155]). In particular, a decrease in the density of GLUT1 and GLUT3 glucose transporters has been reported ([@b225]). Overall, these alterations should induce metabolic changes characterized by an important decrease in CMR~glc~; since CMR~O2~ is supposed to be less decreased, this should elicit an increase in the CMR~O2~/CMR~glc~ ratio, characteristic of a shift towards aerobic metabolism ([@b61]).

Amyloid-β
---------

A number of *in vivo* neuroimaging techniques, which can reliably and noninvasively assess aspects of neuroanatomy, chemistry, physiology, and pathology, hold promise as biomarkers ([@b51]): Apolipoprotein E4 (apo E4) is a component of both the AP and the tangles of hyperphosphorylated tau that characterize AD ([@b166]). Furthermore, in AD early accumulation of AP in several brain regions as well as in the vascular compartments has been demonstrated ([@b166]). Amyloid angiopathy induces a structural alteration of the vessel wall, an endothelium-dependent perturbation of the cerebrovascular reactivity and an increase in the BBB permeability ([@b21]) possibly leading to hemorrhage and ischemia ([@b123]). Moreover, intra-arteriorlar injection of AP reduces the internal diameter of vessels and thereby can decrease CBF and/or energetic supply to the cerebral parenchyma ([@b53]). Accordingly, several studies of cerebral ischemia have shown similar alterations. Indeed, chronic hypoperfusion in the rat has been found to induce alterations of brain capillaries associated with an over-expression of the AP precursor, changes in the function of glucose transporters, and dysfunction of the cholinergic system ([@b100]). Currently, different tools that enable direct, quantitative detection of AP deposits found in AD support the existence of an excellent biomarker for different imaging modalities and are part of current experimental research ([@b51]).

Nitric oxide pathways
---------------------

NOS is supposed to be the pivotal factor in the pathogenesis of different subtypes of dementia, especially AD ([@b126]; [@b198]) demonstrating (i) the release of NO from cerebral endothelial cells to produce vasodilatation, a fairly well established reaction ([@b93]); (ii) NO produced by eNOS to play a key role in vascular tone and blood pressure control, and to inhibit platelet and leukocyte adhesion to the endothelium, a process that may down-regulate proinflammatory events ([@b93]); (iii) the stimulation angiogenesis via vascular endothelial growth factor reduces shear stress on the vessel wall and, consequently, protects endothelial cell function ([@b126]). NOS dysfunction may therefore disrupt the delicate balance between the brain's energy requirements and blood supply, and render the brain more vulnerable to (ischemic) injury ([@b93]).

NO had been shown to diffuse toward the lumen of blood vessels where it helps maintain CBF, by reducing blood viscosity and resistance ([@b173]). However, normal blood flow can be compromised through physical or chemical stimuli affecting eNOS levels localized in the endothelial cell caveolae (small invaginations in the plasma membrane of endothelial cells involved in cell signalling) ([@b82]; [@b92]). Thus, deregulation of vascular NO production can occur from chronic cerebral hypoperfusion ([@b173], [@b174]) as follows: chronic cerebral hypoperfusion below a critically attained threshold initiates eNOS activation and deregulation of NO release from the endothelium in the hippocampus and endorhinal cortex, results in an increased vascular resistance or blood viscosity and causes micro-environmental hemorheological and hemodynamical disturbances ([@b174]). This effect of altered mechanotransduction on eNOS activity up-regulates NO release in order to reset baseline values and diminish the molecular and cellular damage caused by hypoperfusion ([@b174]; [@b92]). In view of failure to achieve homeostasis, depletion of basal NO levels results in the incapability (i) to regulate normal vascular perfusion, (ii) to block granulocyte adhesion in blood vessels, (iii) to prevent proinflammatory intraneuronal reactions, and (iv) to maintain endothelial cell conformation, resulting in endothelial cell shape distortions ([@b93]). The latter phenomenon may explain basement membrane thickening commonly found regionally in AD brain capillaries and potentially seen as a compensatory reaction to increased interendothelial distance created by NO deregulation ([@b174]). Endothelial cell distortion would also permit mobilization of the powerful vasoconstrictor, endothelin-1, and impair GUT-1 activity, the molecule responsible for glucose transport into brain ([@b93]). Thus, AP compromises the ability of cerebral endothelial cells to produce vascular relaxing factors, impairs the ability of cerebral blood vessels to maintain adequate flow during hypotension, and attenuates increased CBF evoked by enhanced NA ([@b93]).

NO appears to affect nuclear factor kappa beta (NF-κβ) directly, a nuclear transcription factor that is widely expressed in CNS and that is involved in the activation of several inflammatory mediators ([@b87]; [@b209]). Simultaneously to NF-κβ activation, in most types of cells, inhibitor IκBα is phosphoryled and proteolytically degraded ([@b87]; [@b28]). After activation, free NF-κβ dimers are translocated into the nucleus, bind to the promoter region of target genes and induce the transcription required for DNA binding and protein dimerization ([@b87]). However, a TNF-α-induced NF-κβ-activation mediates the expression of adhesion molecules on the endothelial surface. NO inhibits NF-κβ transcriptional activation in a variety of cells, including monocytes and endothelial cells ([@b87]). When NO is activated by TNF-α, the NF-κβ inhibitor, inhibitor of NF-kappaBalpha (IκBα), is no longer stabilized and inflammatory cytokines, such as interleukin-1 and interleukin-6, are activated in the brain ([@b87]; [@b28]). Structural microvessel pathology, which is frequently observed in AD brains, results in basement membrane thickening, buckling of the lumen, and distortion of the endothelium ([@b263]). Such histopathological changes will alter normal NO release from the endothelium, allowing IκBα degradation and thereby preventing proinflammatory downregulation via inhibition of NF-κβ ([@b87]). Thus, it is possible that endovascular NO, derived from eNOS, may inhibit NF-κβ tonically under nonstimulated conditions ([@b92]). However, during advanced physiological aging, enhanced by vascular risk factors reducing cerebral perfusion further, this mechanism may be lost, increasing the sensitivity to NF-κβ-activation ([@b87]). In agreement with the hypothesis connecting vascular NO levels with AD is the finding that in the presence of NO donors, TNF-α fails to stimulate NF-κβ released from endothelial cells, allowing NO to stabilize the NF-κβ inhibitor, IκBα, and to prevent its degradation ([@b87]). The binding of NF-κβ to the NF-κβ binding site in the inducible NOS promoter plays a crucial role in the transcriptional regulation of the inducible NOS gene ([@b87]). Furthermore, NO donors can directly inhibit the DNA binding activity of NF-κβ ([@b87]). Briefly, NO derived from eNOS has the ability to downregulate proinflammatory events by inhibiting NF-κβ activation of proinflammatory cytokines leading to microglial activation and neuronal damage ([@b80]).

Neurovascular hypothesis
------------------------

Neurovascular uncoupling suggests various neurovascular related pathogenic mechanisms for the origin of AD ([@b92]). Faulty clearance of AP across the BBB by aberrant angiogenesis or endothelial aging process could lead to formation of vascular amyloid lesions ([Figure 4](#fig4){ref-type="fig"}) ([@b263]). Inefficient AP proteolysis amplifies insufficient AP BBB clearance, whereas AP vascular accumulations stimulate proteasome-dependent degradation of the lipoprotein receptor-related protein (LRP) clearance receptor and is antiangiogenic ([@b263]).

![Neurovascular mechanism of Alzheimer's disease. ([@b264]).\
**Abbreviation:** BBB, blood--brain barrier.](ndt0403-585-04){#fig4}

As suggested by [@b264], premature cerebrovascular senescence owing to atherosclerosis, cerebral amyloid angiopathy and/or elevated soluble AP concentration can result in loss of endothelium-dependent CBF regulation, in neurovascular uncoupling, and in brain hypoperfusion ([@b263]). Islets of regressed and degenerated microvessels consequent to aberrant angiogenesis could act as seeds for the dense-core amyloid plaques and might activate the neuroinflammatory response ([@b263]), but our understanding of the mechanisms by which vascular dysregulation alters brain function is still rudimentary.

The state-of-the-art-imaging
============================

Biological dementia process begins years before it is diagnosed clinically ([@b162]) ([Figure 5](#fig5){ref-type="fig"}). The optimal time to initiate a neuroprotective, therapeutic step is during the preclinical period of the disease, when neuronal degeneration has begun, but cellular and biochemical damage is not yet sufficient for symptoms to manifest ([@b147]). The ability to identify this preclinical state is currently very limited ([@b92]; [@b37]). The most useful strategy is to identify "at risk" subgroups and to search for preclinical neurodegeneration in these enriched populations ([@b263]). The promise of achieving diagnostic specificity through neuroimaging lies with the potential identification of pathognomonic proteins ([@b147]).

![Evolution of sporadic Alzheimer's disease in view of aging and vascular risk factor.\
**Abbreviation:** APP, amyloid precursor protein.](ndt0403-585-05){#fig5}

Recent advances in imaging AP, one of the hallmarks of AD, offer such a technological breakthrough and the possibility for more efficient assessment of antiamyloid interventions as well as specific noninvasive diagnostic capabilities ([@b147]).

Structural imaging
------------------

Clinical symptoms of AD result from synaptic dysfunction that may be associated with or precedes neuronal loss, although the underlying mechanisms are unknown ([@b233]). Neuropathological studies have implicated the gray matter of the medial temporal lobe as an early site of pathological involvement in AD (consistent with the characteristic amnesic presentation in this disorder), and many IT have therefore focused on this part of the brain ([@b2]; [@b182]). MRI enabled the visualization of specific structures within the medial temporal lobe, such as the hippocampus itself, the parahippocampal gyrus, subiculum, entorhinal cortex, and amygdale ([@b37]) with good clinical correlations to dementia (Earnest et al 1954).

The future focus of high-resolution structural MRI on these areas that are affected earliest in AD (ie, entorhinal cortex and hippocampus) may increase diagnostic precision ([@b37]). With the ability to acquire rapidly high-contrast, high-spatial-resolution, three-dimensional IT ([@b140]; [@b241]), sophisticated brain-mapping algorithms identify complex, shifting patterns of brain structural deficits, revealing where, and at what rate, the path of brain deterioration in illness deviates from normal ([@b40]). Results vary, depending in part on the specific measurement approaches (eg, volumetric, planimetric, linear), and many investigations suffer from limitations similar to those described for the qualitative mesiotemporal atrophy study ([@b191]). The measures of the temporal cortices, including the amygdala, hippocampus, and inferior temporal lobes, along with the anterior cingulate cortex, associated with the largest magnitudes of effects, and, hence, these could serve as the most useful structures to help clinicians differentiate AD from physiological aging ([@b191]).

### Cerebrovascular disease

Silent cerebrovascular brain damage is associated with diminished cognitive performance in older people ([@b81]) suggesting that CVD is associated with increased risk of mild cognitive impairment and of conversion to dementia ([@b203]). In addition, the presence of CVD may influence clinical presentation and neurobiology of AD and seem to contribute to determine cognitive impairment in an additive fashion ([@b203]), suggesting that cognitive impairment in stroke patients may be related to cortical neuronal dysfunction rather than purely subcortical change ([@b139]). Moreover, cortical regions not obviously infarcted may have dysfunctional neurons, the pathophysiological basis for which needs further study ([@b203]).

Cholinergic deficits in VaD are due to ischemia of basal forebrain nuclei and of cholinergic pathways and can be treated with the use of the AchE inhibitors used in AD ([@b55]). Since the response in AD to AchE inhibitors might differ according to the magnitude of the cerebrovascular contribution, estimating the vascular burden might also help to understand the variability of the response of AD patients to drug treatment ([@b55]). For isolated subcortical CVD, a particular clinical picture does not characterize its association with AD, and the additional diagnostic potential of IT is huge again ([@b103]). Knowledge is lacking in determining the contribution of subcortical CVD to cognitive impairment alone or in addition to AD ([@b84]). Notably, the impact of number, size and type of lesions on cognitive impairment is unclear ([@b84]). A recent finding supporting this hypothesis is that corpus callosum atrophy -- a proxy of global axonal loss -- is strongly associated with cognitive impairment independently of any effect of white matter lesions depicted on T2 weighted MRI ([@b181]). Moreover, lacunes and other white matter lesions may have different impacts on cognitive impairment, as the first consists pathophysiologically of complete interruption of axonal fibers on pathology, whereas the second is related to incomplete infarction and demyelination ([@b129]). Lastly, not all white matter changes detected by imaging techniques are alike ([@b129]). Patchy areas of hypodensity in the white matter on CT and irregular and confluent white matter hyperintensities on MRI have been suggested to be due to ischemia, whereas other types of hyperintensities seem to be related more often to nonischemic changes ([@b129]). Punctuate lesions can be an early stage of confluent lesions, but sometimes there seems to be no pathological substrate ([@b129]). Diffuse and homogenous periventricular hypodensity of the white matter on CT and smooth periventricular hyperintensities on MRI are due to an increased water content, demyelination, and subependymal gliosis caused by nonischemic alterations of the periventricular fluid dynamics ([@b129]). It was found that diffusion anisotropy which correlates with the apparent diffusion coefficient (ADC) mapping in MRI, did reflect mental ability and was reflected by physiological aging when a series of measurements was performed in the centrum semiovale -- a brain region that at least in part contains watershed areas ([@b136]). However, the altered fractional anisotrpy and ADC values in the genu of the corpus callosum of AD patients presumably reflect the microscopic changes of white matter degeneration in AD and vary with disease severity ([@b115]; [@b136]).

While diffusion-weighted MR imaging (DWI) is used primarily for the investigation of stroke by using the strong sensitivity to ischemia ([@b115]; [@b136]), the ADC maps that can be generated from the same image sets seem to contain further information regarding tissular pathophysiology: indeed this has been demonstrated in both animal and now in human models of stroke where the ADC seems not just to reflect the presence or absence of a lesion but to correlate with the underlying hemodynamic pathophysiology ([@b136]). The changes associated with AD are particularly interesting because diffusion tensor imaging (DTI) within the white matter may be abnormal in the early stages of AD and has the potential to monitor the course of the disease ([@b167]). Such MRI can give information very similar to that obtained by SPECT and PET to detect cortical atrophy and are very sensitive early indicators of hippocampal dysfunction ([@b259]; [@b167]). The combination of macro- and microstructural imaging parameters areas could therefore be promising in early detection of neurodegenerative processes ([@b167]). The main potential advantages of DWI over SPECT or PET include that this IT does not use radioactive isotopes, has superior spatial resolution and can be done in a single session with structural MRI, thereby reducing total examination time in detecting the water diffusivity caused by neuropathological change in AD and vascular dementia.

### Differentiating Alzheimer's disease from other forms of degenerative dementia

Some infrequent types of dementia have a relatively specific imaging pattern and, in conjunction with typical clinical findings, can be easily distinguished from AD approaching the accuracy of neuropathology ([@b37]). The morphological pattern perhaps most specific is that of extremely severe frontopolar and temporopolar atrophy of the cortical layer and white matter association of the frontal (ballooning) and temporal horns ([@b34]). Recent advances in imaging AP, one of the hallmarks of AD, offer a technological breakthrough and the possibility for more efficient assessment of antiamyloid interventions as well as specific noninvasive diagnostic capabilities ([@b147]).

DWI-MRI is sensitive to microscopic motion of water molecules in cerebral tissue ([@b136]). Its primary application has been in the diagnostic evaluation of acute cerebral ischemia ([@b136]). The IT has also been applied to study patients with AD, postulating that pathological destruction of cell membranes, with subsequent loss of myelin and axonal processes due to Wallerian degeneration, increases the water diffusion in the hippocampus and afferent white matter tracts ([@b236]). Such pathological changes manifest by an increased apparent DWI; DTI enables measurement of directionality or asymmetry of microscopic water movement in tissue ([@b115], [@b114]; [@b136]). Such asymmetric diffusion, known as anisotropy, is seen in normal white matter, since the integrity of white matter tracts that allows diffusion of water preferentially parallel, rather than perpendicular, to the tracts ([@b236]). Recently, the IT has been applied in human studies of AD ([@b236]; [@b114]) indicating that physiological aging without dementia is characterized by significant changes in the white matter most prominently in anterior brain regions ([@b236]; [@b73]). The dissociation between the regional effects of aging and dementia suggests that the mechanisms underlying age-associated cognitive decline are distinct from those underlying AD dementia ([@b73]).

The mild increase in OEF seen in AD can be interpreted as evidence of participation of the vascular factors in the reduction of energy metabolism ([@b169]). Since vascular reactivity and vascular transit time were well preserved in AD, the mild increase of OEF is associated with vascular involvement possibly at the level of capillary and BBB, but not at the level of arterioles ([@b169]).

Magnetic resonance spectroscopy
-------------------------------

Magnetic resonance spectroscopy (MRS) is an application of MRI that allows noninvasive assessment of a number of local metabolite in brain tissue ([@b132]). The presence of altered membrane metabolism in AD creates opportunities for both phosphorus and proton MRS investigations of brain chemistry where conventional structural imaging appears normal ([@b115]). Phosphorous MRS allows the simultaneous observation of a number of membrane phospholipid precursors and breakdown products; a loss of membrane integrity would likely change the relative ratio of these compounds compared to their levels in healthy tissue ([@b246]; [@b131]). Less robust evidence using phosphorous MRS has shown significant phosphocreatine decline and increments in the cell membrane phosphomonoesters in the early, and possibly asymptomatic, stages of the disease ([@b246]). Significant relationships between measured metabolites and cognitive indices in patients with mild cognitive impairment and AD have been reported ([@b31]). In addition, phosphodiester concentration has been found to correlate strongly with AD plaque counts ([@b131]). MRS of AD has therefore introduced new pathophysiologic speculations ([@b246]). Studies of automated MRS for AD diagnosis have reported high sensitivity and moderate specificity, but are yet to test prospective samples ([@b246]). As described earlier in this review, selective decreases in temporoparietal perfusion have also been associated with the diagnosis of AD using PET (Jagist 2001). Since cerebral metabolism is closely coupled to CBF, these brain regions might demonstrate altered bioenergetic indices, which could be detected using phosphorus MRS ([@b246]). In contrast to consistent findings of the *in vitro* studies with respect to membrane biochemistry, the findings *in vivo* are extremely variable for AD ([@b109]): these studies suggest a possible role for MRS in early diagnosis and for surrogate biochemical markers for monitoring disease progression and therapeutic response.

Proton MRS allows *in vivo* assessment of different metabolites like *N*-acetylaspartate (NAA), glutamine and glutamate, GABA, myo-inositol (Ins), glycine, mobile choline moieties, creatine (Cr) and phosphocreatine, lipids, and lactate ([@b74]). *N*-acetylaspartate is present primarily in neurons, but not in glial cells or other nonneuronal tissue ([@b131]). Although the exact metabolism of *N*-acetylaspartate remains unclear, *N*-acetylaspartate is generally thought to represent a marker of neuronal function ([@b131]). The *N*-acetlyaspartate level is decreased in cases of neuronal loss or damage yet but may return to normal levels during recovery suggesting a possible re-synthesis of the *N-*acetylaspartate pool ([@b226]). Elevated myo-inositol levels mark gliosis, membrane dysfunction, and/or cytoskeletal abnormalities ([@b74]). Elevated choline levels reflect cellular proliferation or myelin breakdown ([@b74]). In both vascular dementia and AD, ratios of NAA/Cr were decreased, which may be attributed to neuronal degeneration and loss. The Ins/Cr-ratios were increased indicating either enhanced gliosis or alteration of the cerebral inositol metabolism ([@b89]; [@b226]; [@b131]). However, the topographical distribution of the metabolic alterations in both diseases differed, revealing a temporoparietal pattern for AD and a global, subcortically pronounced pattern for vascular dementia ([@b89]; [@b74]). Furthermore, patients suffering from vascular dementia had remarkably enhanced TMA (tetramethylammonium)/Cr ratios, potentially due to ongoing degradation of myelin ([@b74]). These metabolite concentrations do not necessarily correlate with disease severity ([@b89]).

With regard to patients at risk of AD, *N*-acetylaspartate and myo-inositol metabolite levels in patients with mild cognitive impairment are between those of cognitively normal subjects and patients with AD ([@b74]). Patients who are positive for the apolipoprotein ε4 allele tend to demonstrate similar findings prior to the onset of dementia or notable anatomical changes ([@b252]; [@b147]). Longitudinal evaluation may allow determining prognosis and treatment in such at-risk patients. Also, MRS measurements have been shown to be a predictor of cognitive scores at follow-up in AD, but not in vascular dementia ([@b252]). Furthermore, few controlled studies have used MRS to monitor treatment effects of muscarinic agonists and AchE inhibitors, demonstrating *N*-acetylaspartate measured by MRS combined with hippocampal volumetry, to provide a highly useful surrogate marker of AD progression in trials of neuroprotective agents ([@b85]; [@b124]).

The model proposed for the coupling between neuronal activity and CMR~glc~ on the basis of studies at the cellular level would be consistent with an initial glycolytic processing of glucose occurring in astrocytes during NA, resulting in a transient lactate overproduction that is shuttled to axons where it is metabolized oxidatively to generate ATP, followed by a recoupling phase during which lactate would be oxidized by neurons (Mostert et al 2004). The spatio-temporal "window" during which a lactate peak could be detected by MRS would depend on the velocity and degree of recoupling between astrocytic glycolysis and neuronal oxidative phosphorylation (Mostert et al 2004). The possible role of lactate in dementia is currently under investigation: there seems to be experimental evidence in animal models that a parallel lactate and pyruvate increase reflects a severe but not a light cognitive impairment ([@b192]).

Difficulties remain in the clinical application -- since MRS data acquisition from the whole brain is technically not feasible, and findings reported in studies may differ between particular regions ([@b113]). It is also important for future MRS studies to clarify the spatial distribution of assessed metabolites and interaction between metabolites ([@b131]).

Neuronuclear imaging in dementia assessment
-------------------------------------------

Hundreds of patients with clinically diagnosed and in some cases histopathologically confirmed AD have been studied using PET measurements of CBF and CMR~glc~ or CMR~O2~ ([@b102]) finding (i) a consistent pattern of focally decreased NA identified with PET that involves neocortical association areas, but spares basal ganglia, thalamus, cerebellum, and the cortex processing primary sensory and motor functions ([@b155]; Herholz et al 1999) ; (ii) the extent of hypometabolism has been correlated with the severity of cognitive impairment and often shows right/left hemispheric asymmetry ([@b155]; Herholz et al 1999); (iii) a decreased global CBF but normal oxygen metabolism ([@b257]); (iv) an increased striatal but not cortical metabolism ([@b204]). The "classic" regional cerebral pattern of bi-parietotemporal hypometabolism has been found to be associated with a high likelihood of AD, and typical patterns have also been identified for many of the other entities, which may clinically resemble AD, but are distinguished histopathologically ([@b155]). Blinded clinical evaluations of PET are capable of differentiating patients with AD from patients with other dementia or from cognitively intact persons ([@b156]). Effects of normal aging on brain function have also been examined with PET. Recent measurements using FDG-PET identified an age-related decline of glucose metabolism in healthy adults, most consistently in frontal cortex; studies of carefully selected subjects find declines to be minimal in glucose metabolism throughout most of the brain areas during physiological aging (Zuchner et al 2004). (18) F-FDG PET indicates that AD-related processes lead to an altered functional relationship between the entorhinal cortex and several cortical and limbic regions, with respect to normal aging ([@b163]). These results suggest that the assessment of coupled CMR~glc~ reductions between the entorhinal cortex and the ipsilateral inferior temporooccipital cortex, besides the typical pattern of cortical reduction, could increase \[^18^F\]-FDG PET diagnostic sensitivity and further underline its inclusion in the clinical assessment of AD in the near future ([@b163]). However, the relatively low spatial resolution of PET may hinder the detection of pathological elements in small anatomic structures, such as a layer of the entorhinal cortex or subdivision of the hippocampus.

Single photon emission computed tomography (SPECT) has historically been the most widely available FIT, and has become the one most commonly employed in the clinical evaluation of dementia ([@b158]). Most SPECT are perfusion-based. Although the specific radiopharmaceuticals and technique differ from those used in PET, the principles of interpretation, as well as the neurobiological processes underlying its use, are similar. The practical differences in its application are (i) a typically worse spatial resolution of SPECT compared with PET, and (ii) an occasional uncoupling between cortical metabolism (usually measured with PET) and perfusion in the presence of certain CVD. Thus, AD studies utilizing SPECT yielded results similar to those using PET, but with less sensitivity and overall accuracy ([@b178]). That expectation has been further underlined through side-by-side comparisons of the two modalities, including studies performed in AD with mild symptoms, and with high-resolution SPECT and PET ([@b223]).

A recent study assessing the accuracy of SPECT in early dementia followed patients longitudinally for a minimum of 2 years after obtaining SPECT with ^99m^TC-HMPAO ([@b117]). Comparing the SPECT of one group progressing to probable AD, and the other remaining stable for at least two years, both subgroups matched for mildness at time of presentation, the progression group can be distinguished from the stable group with a sensitivity of 78% and a specificity of 71% ([@b117]). A similarly designed study with PET has recently found that progression and nonprogression patients could be distinguished on an average of 3.0 years in advance with a sensitivity of 93% and a specificity of 74% ([@b172]). The higher diagnostic and prognostic sensitivity of PET may be especially relevant in identifying the disease in its earliest stages, in order to target patients for therapy when neurodegeneration is minimal ([@b172]). PET may have high diagnostic accuracy, but adding it to the standard diagnostic regimen of AD would yield limited, if any, benefits at very high costs (McMahon et al 2003).

Genetic risk factors for AD have been identified. The ε4 allele of the apolipoprotein E gene is associated with a significantly increased risk of developing AD of senile onset; overall, those with the ε4/ε3 or ε4/ε4 genotype are more than twice as likely to have AD compared with individuals with the ε3/ε3 genotype ([@b162]). FDG-PET have linked the ε4 allele to hypometabolism in the posterior cingulated, parietal, and temporal cortex, and have identified greater metabolic asymmetry in nondemented relatives of individuals with probable AD ([@b130]). Furthermore, significant metabolic decline in these regions has been observed in those who have inherited the ε4 allele measured by repeated PET in the same subjects over a 2-year interval ([@b130]).

The majority of PET in the memory-impaired population used FDG as a radiolabeled tracer. Most recently, a new radiolabeled tracer, known as 2-(1-{6-\[2-\[^18^F\]fluoroethyl(methyl)amino\]-2naphthiyl}ethylidene)malononitrile or \[^18^F\]FDDNP, has been developed ([@b175]). This tracer is reported to target the amyloid-β senile plaques and neurofibrillary tangles in AD ([@b175]). Additional ligands are in the preclinical development phase.

### Neuronuclear imaging of neurotransmitter system

#### The acetylcholine system

A direct demonstration of cholinergic receptor function, however, may provide a method to select patients for treatment ([@b77]; [@b266]) as cholinergic mechanisms have been shown to control amyloid precursor protein processing and the number of muscarinic M2-acetylcholine receptors is decreased in brain regions of patients with AD enriched with senile plaques ([@b266]). Similarly, demonstration of treatment effects on neurochemical changes of cellular levels by IT will be important for the refinement of pharmacotherapy in dementia ([@b231]). Both, presynaptic deficits to determine the possible need for cholinergic therapy and post-synaptic deficits to assess the likelihood of successful response have to be studied ([@b77]). Two SPECT ligands are currently used: (i) iodobezovesamicol (IBVM) as a marker of ACh terminal density, which has successfully demonstrated marked reduction in patients with NINCDS diagnosed probable AD ([@b125]). Studies have demonstrated that brain regions showing IBVM deficits in AD are similar to those showing reductions in CMR~glc~ and CBF using PET or SPECT ([@b125]). ^123^I-(R,S)QNB (iodine-labeled 3-quinuclidinyl benzilate) or ^123^I-(R,R)QNB binds to muscarinic receptors ([@b254]) and has been used to show that there is little receptor density reduction in patients with mild AD but varying degrees of reduction in moderate-to-severe AD.

#### The dopamine system

Specific SPECT ligands for dopamine transporter (FP-CIT, β-CIT, IPT, TRODAT) provides a marker for presynaptic neuronal degeneration ([@b144]). Striatal uptake correlates with disease severity, in particular bradykinesia and rigidity, and monitoring of progression assists in clinical trials of potential neuroprotective drugs ([@b144]). The dopamine transporter ligands β-CIT and FP-CIT are of particular interest in dementia, and both are labeled with iodine-123 ([@b52]). The main difference between these compounds is the recommended imaging time, which is 24 hours post-injection for β-CIT and around 5 h for FP-CIT ([@b144]). Although the most obvious use of these compounds is the early detection of Parkinson disease and differentiation from similar presentations such as essential tremor and vascular parkinsonism, another likely application is the differentiation of DLB from AD ([@b144]): abnormal results in DLB, normal in AD. Features of DLB, the second most common cause of degenerative dementia, include progressive cognitive deterioration, often associated with levodopa-unresponsive parkinsonism, fluctuations of cognitive functions, and psychotic symptoms (visual and auditory hallucinations, depression) ([@b144]). In a study of both CBF and dopamine transporter binding (using β-CIT), a subtle difference in perfusion patterns was found and a greater degree of occipital hypoperfusion was found in DLB as compared with AD ([@b52]).

Techniques for imaging amyloid-β *in vivo*
------------------------------------------

Imaging of AD progression would greatly facilitate the discovery of therapeutics, and a wide range of ligands are currently under investigation for the AP detection by PET ([@b135]) (see [Table 1](#tbl1){ref-type="table"} and [Table 2](#tbl2){ref-type="table"}).

###### 

Comparison of techniques for in vivo imaging of amyloid β ([@b13])

  Technique     Cross-sectional resolution (mm)^1)^   Ionizing radiation   Volume         Invasivness
  ------------- ------------------------------------- -------------------- -------------- -------------
  PET           2--6                                  Yes                  Entire brain   No
  SPECT         1--10                                 Yes                  Entire brain   No
  MRI           0.1--1                                No                   Entire brain   No
  Multiphoton   0.001                                 No                   0.2 mm^3^      Yes

**Abbreviations:** PET, positron emission tomography; SPECT, single photon emission computed tomography; MRI, magnetic resonance imaging; mm, millimetre.

###### 

Agents for in vivo imaging of amyloid-β ([@b13])

  Imaging agent    Imaging technique   Signal-to-noise ratio
  ---------------- ------------------- -----------------------
  Thioflavin       Multiphoton         High
  Thiazine Red R   Multiphoton         High
  (MeO-XO)~4~      Multiphoton         High
  BTA-1            Multiphoton         High
  \[^18^F\]FDDNP   PET                 Low
  Aβ peptides      Multiphoton         Moderate
  Antibodies       Multiphoton         Very high

**Abbreviations:** BTA-1, thioflavin T; PET, positron emission tomography; FDDNP, \[(2-fluoroethyl) (methyl) amino\]-2-naphthyl\]ethzlidene) malnonitrile.

The requirements for successful amyloid detection and quantification include the availability of an AP-specific radioligand that incorporates a PET radionuclide within its structure ([@b135]). As spatial resolution of PET is relatively low, PET is unable to detect individual receptors, PET will not depict individual plaques ([@b135]). Instead, PET should provide a quantification of the amyloid density in different brain regions and demonstrate differences between regions containing high and low densities of AP ([@b135]). AP-Imaging can provide objective measures of preclinical disease state, when its changes in the follow-up are measured serially ([@b177]). Such information can be used in prevention trials or in monitoring of progression and effectiveness of AD treatment.

Different strategies are used to develop compounds suitable for AP-IT in humans ([@b177]). Monoclonal antibodies against AP or peptide fragments have limited the up-take by the brain when tested in patients with AD if tested for immune therapy of AD ([@b64]). When putrescine-gadolinium-β-amyloid has been injected into transgenic mice over-expressing amyloid, labeling has been observed with MRI ([@b247]) creating an opportunity for the noninvasive investigation of the longitudinal development of the plaques in animals and perhaps humans. The small molecular approach for AP-IT has so far been most successful ([@b78]). The binding of different derivatives of Congo red and thioflavin has been studied in human autopsy brain tissue and in transgenic mice ([@b175]). Agents that recognize AP should improve imaging contrast and detection sensitivity ([@b78]). Suitable agents for detection of AP must meet several criteria: (i) the compound must bind to AP with high specificity; (ii) the reagent must pass the BBB in sufficient amounts to allow detection ([@b138]). This requires that the compound is relatively small and lipophilic ([@b175]). The reagent should bind with high affinity to allow retention of the compound specifically bound to AP while the free and nonspecifically bound compound clears from brain ([@b138]). Two compounds, fluorine-18-labelled-FDDNP and carbon-11-labelled-PIB, both show more binding in the brains of patients with AD than in those of healthy people ([@b175]). Attempts have been made to detect amyloid using \[^18^F\]FDDNP, labeled senile plaques and perineuronal nets in tissue sections from AD brain; however, specificity for these neuropathological lesions is not clear ([@b1]). Perineuronal nets are a specialized form of extracellular matrix and consist of large aggregating chondroitin sulfate proteoglycans, with hyaluronan and tenascin as main components, which surround subpopulations of neurons ([@b160]). The glycosaminoglycan components of perineuronal nets form highly charged structures in the direct microenvironment of neurons and thus might be involved in local ion homeostasis ([@b160]).

Taken together, perineuronal nets store associative memory, do not involve long-term potentiation, and are also loci for AD pathophysiology contributing to or causing early memory loss in clinically manifested AD ([@b3]). PET revealed good BBB permeability, and a sufficient bioavailability of different radiolabelled probes in AD patients as compared to controls ([@b1]; Niwa et al 2002). Unfortunately, nonspecific accumulation of the very lipophilic \[^18^F\]FDDNP is high in white matter areas ([@b175]). \[^18^F\]FDDNP initially accumulates most in the pons (an area without significant numbers of plaques or tangles) and least in the hippocampus (an area of severe pathology) ([@b175]).

Besides the first steps of ^19^F and ^1^H MRI using a fluorine-containing probe in animals ([@b78]), no method that does not involve artificially breaking the BBB has captured AP *in vivo* with sufficient sensitivity and specificity throughout the brain in a definitive manner that could be confirmed by subsequent immunohistochemestry. Continuing engineering efforts to improve spatial resolution are underway in MRI, which may enable IT of individual plaques with contrast probes ([@b180]) enabling early diagnosis and also provide a direct measurement of the efficacy of antiamyloid therapies currently being developed.

Microscopy
----------

*In vitro* studies indicate that amyloid plaques contain multiple binding sites that can accommodate structurally diverse compounds, providing flexibility for radiopharmaceutical design of AP imaging agents ([@b148]). Compared with large biomolecules, small molecule radiotracers are often readily accessible through chemical synthesis and can display superior brain permeability (Christie et al 2001). Several small molecule AP-imaging radioligands display high binding affinities to AP and sufficient brain penetration for imaging studies ([@b12]; [@b44]). Very specific detection of AP can be obtained with antibodies targeted against AP ([@b44]). Antibodies enter the CNS in very small amounts when administered peripherally but have not been successfully used for IT yet (Christie et al 2001). However, fluorescently labeled anti-AP antibodies were applied directly to the brains of transgenic mice and were detected with multiphoton microscopy ([@b44]). The antibodies labeled AP within a few hundred micrometers from the surface of the cortex with high sensitivity and specificity ([@b12]). Surprisingly, also a rapid clearance of the labeled AP has been demonstrated, confirming the usability of an immunotherapeutic approach to treat AD (Christie et al 2001). It is possible that manipulations that increase BBB permeability for labeled antibodies would further improve IT.

Multiphoton microscopy allows very high resolution (\<0.001 mm) imaging of microsopic structures with high sensitivity ([@b12]). This light microscope-based technique depends on detecting fluorescence (either autofluorescence or from a contrast reagent), though no radioactive tracers are necessary (Christie et al 2001) using a pulsed near-infrared laser to excite fluorescence for deeper penetration than visible light microscopy not scattering tissue, and optical tomography with restricted excitation volume (Christie et al 2001). The technique depends on an invasive technique to allow access to the brain, and imaging depths of about 500 µm are achievable leading to a very small imaging volume within the cortex compared to the size of the brain (Christie et al 2001). Fluorescent contrast reagents with high specificity result in very high contrast images of immunohistochemically defined microscopic structures (Christie et al 2001; [@b12]) allowing direct examination of the natural history of plaques and evaluation of antiplaque therapeutics in models of AD ([@b13], [@b12]).

*In vivo* imaging has been performed with fluorescent derivatives of thioflavin T and Congo red ([@b175]). Both compounds have been used as histochemical stains for fibrially amyloid-β deposits: They are small, lipophilic derivates and enter the brain rapidly. Multiphoton microscopy is used to identify the labeled plaques in transgenic mouse brain 30 min after intravenous injection or 24 h after intraperitoneal injection (D'Amore et al 2004). The fluorescent reagents specifically labeled senile plaques and cerebrovascular amyloid ([@b175]). They have near ideal properties for AP-imaging, and multiphoton microscopy demonstrates that these compounds label immunohistochemically defined AP in transgenic mice over-expression of mutant human amyloid precursor protein (D'Amore et al 2004). Radiolabel led versions of methody-XO4 and BTA-1 may also be excellent candidates for PET in AD (Schmidt et al 2001; Kleindienst et al 2004).

Functional imaging methods other than single photon emission tomography and positron emission tomography
--------------------------------------------------------------------------------------------------------

FMRI offers a method to indirectly measure functional brain changes associated with NA ([@b67], [@b66]) being similar in its use to PET ([@b171]). Both methods are able to indirectly measure NA in individual patients because of changes in blood properties ([@b171]). The main type of fMRI is the blood oxygen level dependent (BOLD) imaging which does not involve the injection of paramagnetic contrast agents and is based on differences in the paramagnetic properties between oxy- and deoxyhemoglobulin to detect regional differences in blood oxygenation, usually in comparison between a NA and a resting task ([@b201]). BOLD contrast MRI is a simple noninvasive method of estimating "perfusion", and combined with a vasodilatory stimulus, may allow estimation of cerebral vascular reserve ([@b168]). BOLD signal change appears to originate from net changes in averaged NA areas of cortex that trigger, in some manner, CVC leading to the measured response ([@b168]). A question directly relevant to imaging AD is whether this coupling is intact and if it is possible to make quantitative comparisons between individuals and groups ([@b68]).

In addition, pharmacological fMRI may help to examine neurochemical changes -- ie, of the cholinergic system ([@b67]) -- in early disease of AD by studying signal reactivity to pharmacological challenge at cellular levels. In addition, a recent study using fMRI showed increased brain activation during memory tasks in APOE-4 carriers in brain regions affected by AD ([@b229]). Such pharmacological MRI have implications for understanding the neurochemical mechanism by which cognitive enhancing medications exert these effects on brain function and for the use of fMRI in early detection and treatment monitoring of AD ([@b66]).

FMRI and examining brain-behavior relationships are recent IT that contribute to dementing illness and are notably improving our understanding of the pathophysiology of the different subgroups of dementia ([@b66]). The results of fMRI of cognitively impaired or at-risk patients have shown increases or decreases in the intensity and extent of NA, as compared with findings in control groups ([@b108]). The discrepancies between increased or decreased NA may have to do with either differing task demands or different levels of compensatory reserve ([@b66]). In addition, the differential response to cholinergic challenge in mild cognitive impairment and AD visualized by fMRI may reflect a difference in the functional status of the cholinergic system between both subgroups, which is in line with recent results showing a differential clinical response to cholinergic treatment ([@b66]).

Three kinds of fMRI to study AD have emerged, all still in their developmental stages. One approach focuses on examining tasks, such as encoding information into recent memory, that are known to be compromised in AD ([@b66]). A second approach examines activation patterns that result from the performance of tasks that are completed successfully but may be more difficult in patients at risk for AD. The idea behind such an approach is that cognitive tasks can serve as "stress tests", with individuals at the earliest stages of the disease requiring more neural activity to reach the same level of performance ([@b86]). A final approach, which has been used in only a few preliminary studies performed to this point, is to image tasks that yield downstream markers of medial temporal function ([@b26]).

Diagnostic evaluation
=====================

CVD and stroke relate to a high risk of cognitive impairment, but also relate to AD: vascular cognitive impairment and dementias extend beyond the traditional multi-infarct dementia ([Table 3](#tbl3){ref-type="table"}). The pathophysiology of vascular dementias includes interactions between vascular etiologies (CVD and vascular risk-factors), changes in the brain (infarcts, white matter lesions, atrophy), host factors (age) and cognition ([@b215]). Variation in defining the cognitive syndrome, in vascular etiologies, and allowable brain changes in current criteria have resulted in variable estimates of prevalence, of subgroups of subjects, and of the subtypes and distribution of putative causal brain lesions ([@b130]).

###### 

Use of different imaging methods to investigate the neurovascular mechanism in Alzheimer's disease ([@b130])

  Technique                  Indications and role
  -------------------------- -------------------------------------------------------------------------------------
  Routine examinations       
  CT/MRI                     Exclusion of disease, anatomy
  MR volumetrics             Hippocampal atrophy
  Semiroutine examinations   
  SPECT/PET                  Global/regional blood flow, metabolic changes
  DWI                        Global/regional dysfunction
  Research                   
  MR volumetrics             Frontal/temporal lobe atrophy, whole brain atrophy; sequential: rate of volume loss
  MRS                        Neuronal loss, abnormal metabolite
  DTI                        Neuronal integrity
  fMRI                       Memory, associative functional dysfunction

**Abbreviations:** CT, computed tomography; MRI, magnetic resonance imaging; MR, magnetic resonance; SPECT, single-photon-emission computed tomography; PET, positron emission tomography; DWI, diffusion weighted imaging; MRS, magnetic resonance spectroscopy; DTI, diffusion tensor imaging; fMIR, functional magnetic resonance imaging.

Subcortical ischemic vascular disease and dementia incorporate small vessel disease as the main vascular etiology, lacunar infarct and ischemic white matter lesions as primary type of brain lesions, subcortical location as the primary location of lesions, and subcortical syndrome as the primary clinical manifestation ([@b235]). It incorporates two clinical entities, "Binswanger's disease" and "the lacunar state" ([@b104]). AD with vascular dementias (mixed dementia) has been underestimated as a prevalent cause in the older population ([@b103]). In addition to simple co-existence, vascular dementia and AD have closer interaction: several vascular risk factors and vascular brain changes relate to clinical manifestation of AD, and they also share common pathogenetic mechanisms ([@b127]). Vascular cognitive impairment is a category aiming to replace the "Alzheimerized" dementia concept in the setting of CVD, and substitute it with a spectrum that includes subtle cognitive deficits of vascular origin, post-stroke dementia, and the complex group of the vascular dementias ([@b55]; [@b158]). So far, there is no standard treatment for vascular dementias, and still little is known about the primary prevention (brain at risk for CVD) and secondary prevention (CVD-brain at risk for vascular cognitive impairment/vascular dementia) (Roman et al 2000). Future focus should be directed to the distinct etiological and pathological factors: the vascular and the AD burden of the brain; the state-of-the-art-imaging, and especially the molecular imaging, has a main place in this research.

Early detection of Alzheimer's disease
--------------------------------------

PET has been used to directly quantify several processes relevant to the status of cerebral health and function, including CBF, cerebral blood volume, CMR~O2~, and CMR~glc~ demonstrating diagnostic and prognostic use in evaluating patients who have cognitive impairment, and in distinguishing among primary neurodegenerative dementias and other causes of cognitive decline ([@b224]). These PET found, that patients with AD may differentially express resting CBF covariance patterns even at very early disease stages ([@b208]). Expression of covariance patterns correlates with cognitive and functional performance measures, holding promise for meaningful associations with underlying biopathological processes ([@b57]; [@b76]).

[@b99], [@b98]) demonstrated deficits in perfusion and metabolism, using ^18^FDG and H~2~^15^O PET in mild AD: at the mild and moderate stages of AD, glucose metabolism is reduced not only in the parietotemporal region but also in the posterior cingulate and precuneus. At the advanced stage of AD, there is also a metabolic reduction in the frontal region ([@b76]). In AD patients, CMR~glc~ is relatively preserved in the pons, sensorimotor cortices, primary visual cortices, basal ganglia, thalamus and cerebellum ([@b76]). Recent investigations revealed that asymptomatic members of AD families have significant parietal and temporal deficits compared to control subjects, and that nondemented people in their mid-fifties with increased genetic AD risk, as conferred by apolipoprotein E allele ε(apoE-4), have significantly lower parietal metabolism than those without the apoE-4 allele ([@b162]). Other brain regions typically affected by AD have also been reported to be hypometabolic in individuals homo- or heterozygous for apoE-4, including posterior cingulate, inferior parietal, temporal, and prefrontal regions ([@b162]).

Differential diagnosis of Alzheimer's disease
---------------------------------------------

Neuropathology and structural MRI have pointed to the medial temporal lobe as the brain region earliest affected in AD ([@b104]; [@b90]). T1-weighted MRI findings provide strong evidence that in mild cognitive impairments, AD-related volume losses can be reproducibly detected in the hippocampus, the entorhinal cortex and, to a lesser extent, the parahippocampal gyrus; they also indicate that lateral temporal lobe changes are becoming increasingly useful in predicting the transition to dementia ([@b162]). The 3-D data acquisition in MRI enables exact calculation of volumes and coregistration of images during follow-up examination ([@b16]). Perfusion MRI may be performed to demonstrate areas of reduced CBV and CBF in vascular dementia and several forms of degenerative brain disorders ([@b16]). The CBF reduction is multifocal and subcortical in vascular dementia and shows a cortical distribution in AD ([@b16]). DWI and DTI of individuals with AD demonstrate changes in whole brain white matter and posterior fiber tract with some evidence suggesting that the posterior fiber tracts are more affected than anterior fiber tract ([@b116]). The pathophysiological basis of DTI effects remains uncertain. In addition, current experimental data suggests that magnitude and BOLD brain response in activated particular brain regions is different in AD (Bondi et al 2004). In addition, a diamine- and gadolinium-substituted derivative of β-amyloid is shown to have enhanced *in vitro* binding to AD AP and increased in vivo permeability at BBB because of the unique Asp/Glu substitutions ([@b179]). Because of MRI contrast enhancement provided by gadolinium, MRI of individual AP in AD brains allows for early diagnosis to other dementia subgroups and also provides a direct measure of the efficacy of anti-AP therapies currently being developed ([@b247]).

Failure of BBB with leakage of serum components into and through the walls of cerebral small vessels leading to neuronal and glial damage may be an important common mechanism in AD and vascular dementia (Zlokovic et al 2004). Together with an intravenous paramagnetic contrast agent, such as gadolinium-DTPA, MRI can also detect and quantify BBB damage ([@b251]). Further studies are required to prove the hypothesis that BBB failure and perforating artery endothelial leakage might be a common pathogenetic mechanism for lacunar stroke, white matter hyperintensities, and dementia. If so, new treatments could be targeted toward this new pathophysiological mechanism to prevent the development of or to reduce BBB leakage.

FDG-PET has revealed glucose metabolic reductions in the parieto-temporal, frontal and posterior cingulate cortices to be the hallmark of AD ([@b162]). Overall, the pattern of cortical metabolic changes has been useful for the prediction of future AD as well as in distinguishing AD from other neurodegenerative diseases ([@b162]). FDG-PET on average achieves 90% sensitivity in identifying AD, although specificity in differentiating AD from other dementias is lower ([@b162]). Moreover, recent MRI-guided FDG-PET have shown that medial temporal lobe hypometabolism is the most specific and sensitive measure for the identification of mild cognitive impairments, while the utility of cortical deficits is controversial ([@b162]).

Comparative accuracy of positron emission tomography
----------------------------------------------------

Since PET have shown that psychological or cognitive activation in mild-to-moderate AD can increase CBF and CMR~glc~ as in normal subjects, a similar finding with BOLD fMRI would demonstrate not the quantity but the topographic pattern of activation to differentiate AD from normal persons.

Although the accuracy of the diagnosis is of critical importance, only few studies addressed this question by providing data of sensitivity and specificity following a representative patient mix ([@b121]). The sensitivity of other diagnostic methods is substantially lower than reported by PET, although the specificity is comparable ([@b76]; [@b154]).

*In vivo* proton MRS enables investigation of specific metabolites within tissues. A comparison between ^31^phosphorus MRS and FDG-PET in AD was unable to find a correlation between phosphorus metabolic and either glucose metabolic or dementia severity; hence, measurement of rCMR~glc~ represents a promising technique, but with uncertain clinical specificity and utility ([@b154]) suggesting that in AD reduced neuronal energy performance and membrane abnormalities contribute to metabolic deterioration ([@b154]).

Prospects for the future
========================

PET and SPECT has come to be quite useful for assessing therapeutical effects of newly introduced AD treatment ([@b149]). A number of questions still need to be addressed; in particular the different time constants for synaptic activity and the metabolic response as the basis of the signals detected with PET need to be considered ([@b149]). In this context, it is likely that the glutamate-mediated coupling at neuron-astrocyte metabolic units in an activated cortical area will be compounded through a mechanism in which the extracellular space acts as a spatial and temporal metabolic buffer ([@b149]). The usefulness of these methods in the clinical routine is promising but there are no data that demonstrate whether they contribute a diagnostic value yet.

Different molecular IT may be useful not only to diagnose different subtypes of dementia but also to monitor therapeutic efforts ([@b194]). For example, carriers of a common AD susceptibility gene have functional brain abnormalities in young adulthood, several decades before the possible onset of dementia. With the increasing options to treat dementia symptoms in the future, this aspect may gain increased interest, and IT may become more and more the target of experimental research ([@b194]).

Conclusion
==========

Cerebral arteriosclerosis or stroke may increase the deposition of AP or the formation of neurofibrillary tangles. Alternatively, they may simply hasten the age at onset of disease, or increase the severity of disease symptoms. Disruption of this regulatory network occurs in response to brain injury, for example, during stroke. Evidence now indicates that cerebrovascular dysfunction is at least an aggravating, concomitant feature of neurodegenerative disorders such as AD. Accumulation of AP is associated with neuronal death in AD. AP induces dysfunction in all cell types of the neurovascular unit and interferes with the function of blood vessels. These effects are mediated through reactive oxygen species. This raises the provocative question of whether AD is secondary to vascular dysfunction in the CNS and, therefore, the neurodegeneration that follows is a consequence of inadequate CBF, altered brain metabolism and failure in physiological functions of brain endothelium, which represents a site at the BBB.

AD IT opens the window to a new direction for experimental research and clinical diagnosis or treatment of AD. This approach could be the basis of longitudinal studies in experimental models of AD to search for biomarkers associated with AP pathologies as well as to track disease course after treatment with candidate pharmacological substances.
